ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
50.4%+3.6 pts over 5 years
Operating margin
33.0%+24.7 pts over 5 years
Net margin
30.1%+10.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +77.1% | +63.3% | +42.4% | +28.1% | |
| Gross profit | +87.2% | +65.4% | +44.6% | +25.1% | |
| Operating income | +150.6% | +137.3% | +87.8% | – | |
| Net income | – | +132.7% | +54.6% | – | |
| Free cash flow | +291.4% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -102.2% | 38.0% | 58.9% | |
| Return on assets | 11.6% | 19.9% | 38.2% | |
| Current ratio | 5.50 | 2.10 | 6.45 | |
| Interest coverage | -30.9× | 8.1× | 441.0× | |
| Inventory turnover | 1.2× | 3.0× | 3.9× | |
| Capex to revenue | – | – | 0.6% | |
| Diluted shares | 845M | 943M | 1.14B |
Where the cash went
Fiscal 2022 to 2026, five years combined
Elite Pharmaceuticals generated $44.29M from operations and spent $9.60M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$44.29M
Used
$9.60M
Capital expenditure$9.60M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin30.1%
×Asset turnover1.27×
×Equity multiplier1.54×
=Return on equity, FY202658.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 30.1% | 1.27× | 1.54× | 58.9% |
| FY2025 | -5.1% | 0.93× | 1.62× | -7.8% |
| FY2024 | 35.5% | 0.91× | 1.44× | 46.5% |
| FY2023 | 10.4% | 0.90× | 1.40× | 13.1% |
| FY2022 | 27.6% | 1.05× | 1.48× | 43.0% |
| FY2021 | 20.0% | 0.99× | 1.91× | 38.0% |
| FY2020 | -12.5% | 0.73× | 6.06× | -55.0% |
| FY2019 | -122.6% | 0.27× | 26.79× | -899.3% |
| FY2018 | -49.2% | 0.23× | 2.16× | -24.3% |
| FY2017 | 39.5% | 0.29× | -8.85× | -102.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
6of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$44.87M
- Cash generatingOperating cash flow above zero$23.75M
- Return on assets improvedROA up on the prior year-5.2% → 46.6%
- Earnings backed by cashOperating cash flow above net income$23.75M vs $44.87M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.88 → 6.45
- No dilutionShare count did not rise1.07B → 1.14B
- Gross margin improvedGross margin up on the prior year47.70% → 50.40%
- More efficientAsset turnover rose1.00 → 1.54